BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31477830)

  • 1. Rho guanine nucleotide exchange factor ARHGEF10 is a putative tumor suppressor in pancreatic ductal adenocarcinoma.
    Joseph J; Radulovich N; Wang T; Raghavan V; Zhu CQ; Tsao MS
    Oncogene; 2020 Jan; 39(2):308-321. PubMed ID: 31477830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MiR-143-3p suppresses tumorigenesis in pancreatic ductal adenocarcinoma by targeting KRAS.
    Xie F; Li C; Zhang X; Peng W; Wen T
    Biomed Pharmacother; 2019 Nov; 119():109424. PubMed ID: 31521891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
    Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
    Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCAT2-mediated BCAA catabolism is critical for development of pancreatic ductal adenocarcinoma.
    Li JT; Yin M; Wang D; Wang J; Lei MZ; Zhang Y; Liu Y; Zhang L; Zou SW; Hu LP; Zhang ZG; Wang YP; Wen WY; Lu HJ; Chen ZJ; Su D; Lei QY
    Nat Cell Biol; 2020 Feb; 22(2):167-174. PubMed ID: 32029896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
    Henry KE; Dacek MM; Dilling TR; Caen JD; Fox IL; Evans MJ; Lewis JS
    Clin Cancer Res; 2019 Jan; 25(1):166-176. PubMed ID: 30228208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lunatic Fringe is a potent tumor suppressor in Kras-initiated pancreatic cancer.
    Zhang S; Chung WC; Xu K
    Oncogene; 2016 May; 35(19):2485-95. PubMed ID: 26279302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dasatinib inhibits the development of metastases in a mouse model of pancreatic ductal adenocarcinoma.
    Morton JP; Karim SA; Graham K; Timpson P; Jamieson N; Athineos D; Doyle B; McKay C; Heung MY; Oien KA; Frame MC; Evans TR; Sansom OJ; Brunton VG
    Gastroenterology; 2010 Jul; 139(1):292-303. PubMed ID: 20303350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of miR-30a-3p Regulation of Oncogenic Targets in Pancreatic Ductal Adenocarcinoma Pathogenesis.
    Shimomura H; Okada R; Tanaka T; Hozaka Y; Wada M; Moriya S; Idichi T; Kita Y; Kurahara H; Ohtsuka T; Seki N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic kinase Pim-1 is modulated by K-Ras signaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells.
    Xu D; Allsop SA; Witherspoon SM; Snider JL; Yeh JJ; Fiordalisi JJ; White CD; Williams D; Cox AD; Baines AT
    Carcinogenesis; 2011 Apr; 32(4):488-95. PubMed ID: 21262926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
    Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
    Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.
    Thomas D; Sagar S; Liu X; Lee HR; Grunkemeyer JA; Grandgenett PM; Caffrey T; O'Connell KA; Swanson B; Marcos-Silva L; Steentoft C; Wandall HH; Maurer HC; Peng XL; Yeh JJ; Qiu F; Yu F; Madiyalakan R; Olive KP; Mandel U; Clausen H; Hollingsworth MA; Radhakrishnan P
    Mol Ther; 2021 Apr; 29(4):1557-1571. PubMed ID: 33359791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
    Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
    Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PUM1 knockdown prevents tumor progression by activating the PERK/eIF2/ATF4 signaling pathway in pancreatic adenocarcinoma cells.
    Dai H; Shen K; Yang Y; Su X; Luo Y; Jiang Y; Shuai L; Zheng P; Chen Z; Bie P
    Cell Death Dis; 2019 Aug; 10(8):595. PubMed ID: 31395860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARHGEF15 overexpression worsens the prognosis in patients with pancreatic ductal adenocarcinoma through enhancing the motility and proliferative activity of the cancer cells.
    Fukushima H; Yasumoto M; Ogasawara S; Akiba J; Kitasato Y; Nakayama M; Naito Y; Ishida Y; Okabe Y; Yasunaga M; Horiuchi H; Sakamoto E; Itadani H; Mizuarai S; Oie S; Yano H
    Mol Cancer; 2016 May; 15(1):32. PubMed ID: 27145964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
    Oria VO; Lopatta P; Schmitz T; Preca BT; Nyström A; Conrad C; Bartsch JW; Kulemann B; Hoeppner J; Maurer J; Bronsert P; Schilling O
    Mol Oncol; 2019 Feb; 13(2):456-479. PubMed ID: 30556643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-628-5p inhibits invasion and migration of human pancreatic ductal adenocarcinoma via suppression of the AKT/NF-kappa B pathway.
    Zhou L; Jiao X; Peng X; Yao X; Liu L; Zhang L
    J Cell Physiol; 2020 Nov; 235(11):8141-8154. PubMed ID: 31957029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
    Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
    Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ETV4 promotes pancreatic ductal adenocarcinoma metastasis through activation of the CXCL13/CXCR5 signaling axis.
    Gao X; Jiang M; Chu Y; Han Y; Jin Y; Zhang W; Wang W; Yang S; Li W; Fan A; Cao J; Wang J; Liu H; Fu X; Chen D; Nie Y; Fan D
    Cancer Lett; 2022 Jan; 524():42-56. PubMed ID: 34582976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.